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Advanced sleep phase disorderCircadian rhythm disorders constitute a group of phenotypes that usually present as altered sleep–wake
schedules. Until a human genetics approach was applied to investigate these traits, the genetic components
regulating human circadian rhythm and sleep behaviors remained mysterious. Steady advances in the last
decade have dramatically improved our understanding of the genes involved in circadian rhythmicity and
sleep regulation. Finding these genes presents new opportunities to use a wide range of approaches, includ-
ing in vitromolecular studies and in vivo animal modeling, to elevate our understanding of how sleep and cir-
cadian rhythms are regulated andmaintained. Ultimately, this knowledge will reveal how circadian and sleep
disruption contribute to various ailments and shed light on how best to maintain and recover good health.
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Behavioral studies using model organisms are stimulating and rela-
tively approachable since the researchers can, for the most part, control
both external and internal variables. These studies have provided us
novel insights into the genetic nature of many interesting behaviors.rights reserved.Predictably, gaps remain when trying to translate what scientists
learn in model organisms to something applicable or useful for
human health conditions. In contrast to model organisms, studying be-
havior in humans such as sleep requirement and preferred sleep–wake
times is a daunting task due to the complexity of confounding
co-morbidities, environmental factors, and the polygenic nature of be-
havioral phenotypes.
Like most organisms, humans exhibit daily behaviors that are
regulated in a circadian (24-hour) manner. Early pioneers of circadian
29C.R. Jones et al. / Experimental Neurology 243 (2013) 28–33biology research, such as Jurgen Aschoff, observed that human behav-
iors under constant conditions exhibited rhythms with an approxi-
mately 24-hour periodicity (Aschoff et al., 1971). Aschoff's studies
in humans revealed the existence of an endogenous biological
time-keeping mechanism. Decades later, studies from model organ-
isms uncovered a molecular clock comprised of many genetic players
that governs the circadian oscillation of physiology and behaviors
through complex methods of regulation (Dunlap et al., 2004;
Hastings et al., 2008). Not surprisingly, there are shared molecular
mechanisms for the molecular clock among diverse organisms,
including Neurospora, Drosophila, rodents and humans. However,
there are also salient differences. For instance, core clock mechanisms
are presumably more widely integrated with other forms of physio-
logical regulation in metazoans compared with unicellular organisms
due to the inherent complexity of intercellular interactions. In addi-
tion, while molecular differences between vertebrates and inverte-
brates cannot be overlooked (Hardin, 2011; Lowrey and Takahashi,
2011), differences between closely related species, such as rodents
and humans, are also expected. For instance, mice are nocturnal and
with circadian period average approximately 23.5 h under constant
darkness (Lowrey and Takahashi, 2011), whereas humans are diurnal
with an average slightly longer than 24 h (Czeisler et al., 1999). More
importantly, the highly polyphasic nature of sleep where dozens to
hundreds of sleep–wake transitions occur every hour in mice
directly contrasts with the single 5–9 hour block of consolidated
sleep in most modern adult humans with only a few sleep to wake
transitions.
Identification of the underlying genetic basis of human circadian
rhythm behaviors was first advanced with the characterization of
the first Mendelian circadian trait, familial advanced sleep phase
(FASP), in 1999 (Jones et al., 1999). This study began with meticulous
phenotypic characterization of a 69 year old woman who had
life-long early sleep–wake onset, which led to the identification of a
large family segregating this behavior. This story pioneered the field
of human sleep genetics at the molecular level, including the search
for rare Mendelian single gene/mutation forms and genome-wide
association studies aimed at discovering novel variants in larger
populations. Since the initial FASP findings, other human circadian/
sleep phenotypes have been attributed to underlying genetic compo-
nents, such as familial natural short sleep (FNSS) (He et al., 2009;
Zhang et al., 2011). Therefore, studies of rare and extreme Mendelian
behavioral traits have established a foundation for identifying human
genetic components for circadian rhythms and sleep behaviors,
which then provide further opportunities for understanding the mo-
lecular mechanisms of these behaviors. This review will outline the
current understanding of the field of circadian rhythm disorders.Fig. 1. Schematic sleep schedules for ASP, DSP, NSS, and ISW in comparison to general
sleepers during each 24 hour period. Black-filled bars represent time spent in sleep.Human circadian rhythm sleep disorders
Human alertness demonstrates a circadian rhythmicity with a
seemingly paradoxical nadir of sleepiness at the end of the day (the
“Maintenance of Wakefulness Zone”) (Strogatz et al., 1987), followed
by a peak in difficulty sustaining wakefulness in the second third of
the sleep period (approximately 3–5 A.M.) and then a gradual in-
crease in alertness until the next evening. Pineal release of melatonin
is stimulated by the suprachiasmatic nucleus of the hypothalamus
(SCN) starting about 1–2 h before habitual sleep onset time and con-
tinuing through the night, unless such stimulation is masked by light
of more than 50–100 lx intensity (Lewy et al., 1980).
The International Classification of Sleep Disorders lists approxi-
mately 60 disorders of human sleep (ASDA, 1997) including circadian
rhythm sleep disorders (CRSD). CRSD usually present as a social prob-
lem in a person's sleep/wake timing. The most common complaints
for CRSD are difficulty initiating or ending sleep at appropriate social
times.Circadian rhythm sleep disorders are classified into the following
types according to the American Academy of Sleep Medicine
(AASM, 2012):
1. Advanced sleep phase disorder (ASPD)
Individuals with ASPD have earlier sleep/wake times than a ma-
jority of the population, whereby the entire sleep–wake cycle of
ASPD is shifted up to several hours earlier with respect to solar time
(Fig. 1) (AASP, 2005). These people are considered “morning larks”.
People with ASPD fall asleep during the “Maintenance of Wakefulness
Zone” for conventional sleepers and tend to wake up alert and ener-
getic in the early morning hours when most people are the sleepiest.
ASPD patients usually present with both difficulty in staying awake to
satisfy domestic responsibilities in the evening and an obligate early
morning awakening before others are active. This can result in signif-
icant sleep deprivation if social responsibilities keep the patient
awake late and their biological clock wakes them up early. ASPD is
more common in the elderly. It is notable that many people have ex-
tremely early sleep and wake times and in whom it is not considered
a disorder. Such individuals may in fact feel virtuous for being the
‘early bird’ that gets the worm. Thus, perception of waking early
may be positive or negative and is really in the eye of the beholder,
underscoring the fact that these clinical classifications are truly be-
havioral phenotypes.
The International Classification of Sleep Disorders criteria for the
clinical diagnosis of ASPD are based on the report of a patient who
seeks medical attention specifically because of a complaint of a
sleep time that is earlier than his/her “desired” sleep schedule
(ASDA, 1997). No (solar) clock times of the habitual morning wake
up are specified, and no measurements of melatonin, temperature,
or other rhythms are required.
2. Delayed sleep phase disorder (DSPD)
DSPD individuals are “night owls” and routinely have later sleep/
wake onset compared to the rest of the population (Fig. 1) (AASP,
2005). Their entire sleep–wake cycle is shifted later with respect to
solar time, and DSPD patients feel wide awake, energetic and moti-
vated until late in the night. Depending on the severity, sleep onset
may be delayed until 01:00 to 06:00 A.M., and the circadian “morn-
ing” increase in alertness does not occur until approximately
10:00 A.M. to 2:00 P.M. DSPD individuals are often sleep deprived be-
cause sleep onset is delayed by the biological clock and morning wak-
ing time is enforced by the alarm clock and social responsibilities.
DSPD is common in adolescents and young adults with an estimated
prevalence of 7–16%. Again, it is important to point out that there
are many night owls who do not consider it a disorder.
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People with free-running disorder have a variable but predictable
sleep–wake cycle that shifts approximately 1 h later every day (AASP,
2005). FRSD is usually associated with a history of either total retinal
blindness or sleep phase delay.
4. Irregular sleep–wake disorder (ISWD)
These individuals have undefined sleep–wake cycles and their
sleep is fragmented into a series of naps that occur throughout the
24-hour day (Fig. 1) (AASP, 2005). A mild symptom of irregular
sleep–wake rhythm is sometimes seen in many neurological disorder
patients (e.g. dementia) and in mentally retarded children. Individ-
uals with this disorder suffer from excessive sleepiness, chronic in-
somnia, or both.
5. Jet lag disorder
This happens when the sleep/wake times of the new location for a
traveler are misaligned with the traveler's internal body clock derived
from his/her original place of abode. The severity increases with the
number of time zones crossed; symptoms are temporary.
6. Shift work disorder
When an individual's work hours are during their optimal sleep
time, this causes sleepiness during the work shift and difficulty
remaining asleep during the new required sleep time. Depending on
the timing of the shift, a person's inherent sleep preference can influ-
ence his/her ability to adjust to the shift work. For example, morning
larks will be able to adjust to early shift work easier than the rest of
the population.
Phenotyping CRSD
The mammalian circadian rhythm system is complicated (Saper et
al., 2005) and whole-organism circadian behavior is further
confounded by strong interactions between the organism and its en-
vironment, especially the perceived photic regime (Takahashi et al.,
2001). That the core circadian “clock” mechanism is relatively inac-
cessible inside the central nervous system creates a further investiga-
tive challenge to measuring intrinsic or “biological” time relative to
the timing of the perceived light–dark cycle. Under laboratory confine-
ment, it is possible to measure the timing of objective markers of
human biological circadian time (e.g. core body temperature or plasma
melatonin levels) relative to the timing of the most recently-
imposed light–dark cycle (the so-called “phase angle of circadian
entrainment”) in a “constant routine” protocol (Mills et al., 1978).
The more prolonged “forced desynchrony” protocol has been suc-
cessfully employed in many human studies to measure the intrinsic
period length, or speed, of the hypothalamic circadian clock
(Czeisler et al., 1986). These laboratory procedures are expensive
for the investigator and time-consuming for the participant. There-
fore, many human circadian studies are ambulatory and report
measurements of various phase angles of entrainment for either
self-reported phase markers (e.g. times of first falling asleep and
final awakening) or objective phase markers (e.g. the time of saliva
melatonin secretion onset) (Burgess and Fogg, 2008) or the onset
time of the daily rhythm of wrist movement (Littner et al., 2003).
Questionnaires such as the Morningness–Eveningness Question-
naire (Horne and Ostberg, 1976) and the Munich ChronoType Ques-
tionnaire (Roenneberg et al., 2003) also have moderately strong
correlations with objective assessments (Duffy et al., 2001; Horne
and Ostberg, 1976) of phase-advanced or delayed sleep–wake
rhythms (i.e. morning or evening “chronotype”) (Roenneberg,
2012). However, inferring intrinsic circadian physiology from ob-
served rhythms in daily behavior outside the laboratory is con-
founded in humans by self-imposed artificial (i.e. non-solar) photicregimes and by the circadian influence of idiosyncratic developmen-
tal, psycho-social, physical/medical, and non-circadian sleep charac-
teristics. Therefore, careful individual human chronotyping includes
consideration of these multiple categories of information.
Familial advanced sleep phase disorder
Molecular genetic studies of CRSD began from familial advanced
sleep phase disorder (FASPD, formerly familial advanced sleep
phase syndrome or FASPS) since it is the first CRSD with identified
mutations. FASPD is an autosomal dominant human sleep trait char-
acterized by stable entrainment of sleep and wakefulness to early
solar times. In the mid-1990s, FASPD was first genetically character-
ized in a Utah family, due to its very dramatic advancement of sleep
phase in the proband (Jones et al., 1999). The proband's sleep phase
was advanced ~4–6 h, in comparison to controls; however, FASPD
subjects' sleep quality and quantity were measurably normal. We
have since then identified a large number of families that exhibit
the FASPD phenotype segregating as an autosomal dominant trait.
Identification of these families afforded the opportunity to search
for underlying genes causative for the advanced sleep phase
phenotype.
PER2
The first FASPD family was large enough to allow for linkage anal-
ysis, which localized the mutant allele to the chromosome 2q
telomeric region (Toh et al., 2001). Positional cloning, cDNA identifi-
cation, and mutation screening of genes within the critical region
identified a single base change in the human Period 2 gene (hPER2).
PER2 is one of the three homologs of the Drosophila per gene, and
the mutation substitutes a serine with a glycine residue at amino
acid position 662 of PER2.
The proband was willing to participate in a time-isolation (under
an environment without any time cues) experiment for three weeks
and showed an ~1 h shortening in her circadian period (“tau”). Fol-
lowing the identification of the mutation, mouse models carrying
the hPER2S662G variant were engineered and period length for
these mice was measured under laboratory conditions (Xu et al.,
2007). Under standard “free-running” constant darkness (DD),
S662G mutant transgenic mice exhibited a near-2-hour shorter
free-running period (tau) and a ~4–6 hour phase advancement of
the behavioral phenotype, which recapitulates the behavioral pheno-
type seen in human subjects.
Mechanistic insights regarding the human clock regulation via hPER2
were partially revealed usingmolecular and biochemical approaches (Xu
et al., 2007). PER2 serine 662 is followed by four additional serines, each
separated by two amino acids (a recognition motif for CKIδ/ε). The
S662G mutation renders PER2 hypo-phosphorylated by blocking phos-
phorylation by CKIδ/ε (Toh et al., 2001; Xu et al., 2007). The mutation
also affected transcript levels for both endogenous mouse Per2 and the
human PER2 transgene in the transgenic mice. Both showed a reduced
level with phase advancement compared towild-type control mice, indi-
cating that PER2S662G is a stronger transcriptional repressor than
wild-type PER2. To further enhance our understanding of the role of ser-
ine 662, parallel investigations with S662D in addition to S662G were
performed. Importantly, S662D transgenic mice demonstrated a longer
tau and exhibited increased mPer2 and hPER2 transcript levels with de-
layed phase in relation to wild-type controls, indicating that PER2S662D
is a weaker transcriptional repressor than wild-type PER2. Together,
these results demonstrate the direct impact of S662 phosphorylation
on PER2 transcriptional activity, which then plays a critical role in setting
the speed of the molecular clock.
PER2 S662G and S662D transgenic mice were also crossed with
CKIδ wild-type transgenic (with 4–5 copies of CKIδ) and CKIδ hetero-
zygous knock-out mice (one copy of CKIδ) to investigate the genetic
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CKIδ does not have any effect on the tau of wild type mouse behav-
ior. However, a lower copy number of CKIδ led to longer tau for mu-
tant PER2 transgenic mice, and a higher copy number of CKIδ caused
the tau of PER2 mutant transgenic mice to be shortened. These re-
sults implied that phosphorylation by CKIδ on another region(s) of
PER2 can modulate tau independently from the S662 region. The
phosphorylation status of S662 also influenced PER2 stability;
PER2S662G is less stable and PER2S662D is more stable than wild
type PER2 (Vanselow et al., 2006). Hence, the stronger repressor is
less stable and the weaker repressor is more stable. This finding
raised the possibility that the suicide model of transcriptional fac-
tors is a likely mechanism for regulating PER2 (and possibly for
other circadian repressors), and this mode of regulation can also
provide a highly sensitive system to track the timing of the clock
(Fu, 2008).Casein kinase I delta (CKIδ)
In the early 2000s, with a growing number of human genome se-
quences in the public databases, it became reasonable to search for
causativemutations using a candidate gene approach since the number
of candidate genes had dramatically increased. A second causative mu-
tation for FASPD was identified in human CKIδ; the mutation substi-
tutes threonine at amino acid position 44 by alanine (T44A) (Xu et
al., 2005). The conservation of threonine at amino acid 44 and the
mutation-induced decrease in phosphorylation of alpha-casein and
PER protein substrates by in vitro kinase assays strongly suggested
the biological relevance of this genetic variant. A BAC transgenic
mouse model carrying CKIδT44Awas generated and the “free-running”
period (tau) was shorter than control mice by ~20 min. The mutant
transgene on a CKIδ knock-out background demonstrated a much
shorter tau (22.7 h) in addition to rescuing the lethal phenotype of
the CKIδ knock-out. Intriguingly, expressing the human CKIδT44A mu-
tation in Drosophila generated flies with a significantly longer period
than control flies (Xu et al., 2005), which highlighted the underlying
differences between mammals and invertebrates.
CKIδ is a critical core component of the molecular clock. To further
explore the clock composition through CKIδ, proteomic studies were
conducted using CKIδ and CKIε. These studies were carried out at dif-
ferent circadian time points to reveal the dynamics of CKI proteomes,
and distinctive potential interacting partners and/or substrates were
found for these enzymes at different circadian times. Importantly, dif-
ferent pools of proteins were identified for CKIδ and CKIε, though
with some overlap, supporting the partially redundant roles for these
enzymes. Prohibitin2 (PHB2) was chosen after the initial in vitro screen-
ing process for further characterization. Interestingly, PHB2 protein
levels were regulated by CKIε, yet its RNA levels were modulated by
CKIδ. Characterization revealed that PHB2 is a novel clock component
and acts as a transcriptional repressor for clock controlled genes in a
CLOCK/BMAL1 independent manner (Kategaya et al., 2012).Familial natural short sleepers
While screening genes for the “extreme early bird” phenotype, a
mutation was identified in human DEC2 (hDEC2). Variant carriers
in this small family were further evaluated and found to possess a
natural short sleeper (NSS) phenotype with a lifelong daily sleep
time requirement of approximately ~6 h (He et al., 2009). Similar
to the FASP human subjects, the FNSS individuals woke up at an ex-
tremely early hour in the morning; however, their sleep onset time
was comparable to conventional sleepers, thus shortening their
total sleep duration by ~2 h each day compared to conventional
sleepers (Fig. 1).DEC2
Using a candidate gene sequencing approach, a point mutation that
changed the amino acid at position 384 from proline to arginine in
hDEC2 was found to co-segregate with the FNSS phenotype. In vitro lu-
ciferase reporter experiments showed that the mutation mitigated
transcriptional inhibitory function of hDEC2. Transgenic mice carrying
this P384R mutation displayed a similarly shorter total sleep time, in-
cluding an activity period (alpha) ~1.2-h longer than wild-type mice.
When the mutant transgene was bred onto a mouse Dec2 knock-out
background, the mice exhibited an evenmore dramatic activity pheno-
type with alpha lengthened by ~2.5 h.
Electroencephalography (EEG) and electromyography (EMG)
were also performed on DEC2 P384R mutant transgenic mice and
their littermate controls to further characterize the sleep phenotype.
Mutant transgenic mice were awake for significantly longer periods
of time during the light phase (when mice are supposed to be
sleeping). Consistently, they showed a significant reduction of both
non-rapid eye movement (NREM) and REM sleep in the light phase
(He et al., 2009). NREM sleep in the light phase was more fragmented
in the mutant transgenic mice than control mice. In addition, the EEG
study also demonstrated that mutant transgenic mice accumulated
less recovery sleep after sleep deprivation.
The function of DEC2 in sleep regulation was also tested in
Drosophila to see whether it gives a conserved phenomenon across
species. This was carried out by generating transgenic flies with either
wild-type or P384R mDec2 expressed in either whole brain or the
mushroom bodies. In agreement with the findings from mammalian
systems, flies with mutant mDec2 expressed in their mushroom bod-
ies demonstrated lengthened activity duration (i.e. a shortened sleep
length) compared to equivalent control flies. All this evidence
supported a role for hDEC2 in regulating sleep homeostasis.
Other clock genes
Interestingly, some mouse models of clock genes have been
shown to have effects on sleep architecture. In mice, the Clock muta-
tion was shown to alter sleep homeostasis (Naylor et al., 2000) and
mice that are deficient for both Cry1 and Cry2 sleep longer than
wild-type mice by almost 100 min (Wisor et al., 2002). Similarly,
Bmal1 (Laposky et al., 2005) and Npas2 (Franken et al., 2006)
knock-out mice were reported to have altered sleep time and archi-
tecture. These findings raise the possibility that the molecular circuit-
ry used to set internal time-of-day might also be utilized, at least in
part, to track and anticipate sleep need (Franken and Dijk, 2009).
Genetic association studies
In addition to searching for genes with Mendelian forms of CRSD,
the rapid advance in human genome sequencing and SNP genotyping
during the last two decades allowed for association studies of human
CRSD (or morningness/eveningness preference) to become possible.
Sleep phase
CLOCK
Association between a polymorphism in the 3′-untranslated re-
gion of CLOCK (3111C to T) and evening preference was first reported
in 1998 using human volunteers (Katzenberg et al., 1998). Individuals
with C/C or C/T genotypes showed an increased evening preference
compared with individuals with the T/T genotype. This CLOCK
3111C/T polymorphism was later found not to be associated with
eveningness by Robilliard et al. (2002). In addition, Robilliard et al.
reported that CLOCK 3111C/T is neither associated with tau length,
nor with delayed sleep phase. Their molecular study further demon-
strated that this polymorphism does not affect CLOCK mRNA
32 C.R. Jones et al. / Experimental Neurology 243 (2013) 28–33translation, hence weakening the value of CLOCK 3111C/T as a marker
for diurnal preference, tau, or delayed sleep phase disorder in
humans. However, the Clock mutation mouse model was shown to
demonstrate phase delays of the rhythm for body temperature, activ-
ity and wake duration in one study (Sei et al., 2001) and delayed lo-
comotor activity under constant light and during lactation in a
separate study (Wakatsuki et al., 2007). These results do support
the possibility that CLOCK mutations/polymorphisms may be associ-
ated with evening preference.
PER3
A length polymorphism in PER3 was reported by Archer et al.
(2003) to be linked to delayed sleep phase disorder and extreme
diurnal preference. This length polymorphism is due to a variable-
number tandem repeat (VNTR, 4 or 5 repeats) in PER3. The shorter
4 allele was found to have a strong association with delayed sleep
phase disorder. They followed up this study and reported that poly-
morphisms in the PER3 promoter are also associated with diurnal
preference and delayed sleep phase disorder (Archer et al., 2010).
However, a recent Norwegian study with 432 subjects was not able
to reproduce these findings (Osland et al., 2011).
Sleep duration
Several genetic association studies for sleep duration have been
conducted. The first report was for more than 700 participants from
the Framingham Heart Study Offspring Cohort using the Affymetrix
100K SNP GeneChip. This family-based study was able to confirm sig-
nificant heritability of sleepiness, usual bedtime, and usual sleep
duration (Gottlieb et al., 2007). Allebrandt et al. applied a more fo-
cused approach using high-density markers from 19 clock genes to
perform a two-stage design association study on two European
populations, South Tyrol and Estonia. In this study, variants in the
CLOCK gene were found to have an association with sleep duration
for these two independent populations (Allebrandt et al., 2010). An-
other genome-wide association study was carried out for seven Euro-
pean populations, totaling 4251 subjects. The meta-analysis for this
study revealed a genome-wide significant signal in the ABCC9 locus
that encodes a pore-forming subunit of an ATP-sensitive potassium
channel (KATP) involved in energy metabolism and in the etiology of
cardiomyopathies (Allebrandt et al., 2011). Interestingly, the authors
also reported that knocking down Drosophila ABCC9 caused shortened
nighttime but not daytime duration of sleep-like behavior in the fly.
Concluding remarks
Identification of mutations that are responsible for various human
diseases has revolutionized the field of biomedical research during
the last twenty years. Many of these are rare diseases where large
families are used to map and clone the causative genes/mutations.
Knowledge of genes and pathways contributing to the pathophysiol-
ogy of rare diseases often opens new areas for studying more com-
mon and non-Mendelian forms of the disease. Genes causing rare
familial Alzheimer's and Parkinson's disease encode proteins that
are central to the pathophysiology of the common sporadic forms of
these diseases (Bertram et al., 2010; Hardy, 2010). A logical extension
of this kind of work in disease genetics is to apply this approach to
even more complex issues such as human behavioral phenotypes
which are subject to large influences of environmental and social fac-
tors. Using human genetics to identify specific genes/proteins that are
critical for specific behavioral phenotypes (especially those that are
associated with human health) is a window into novel biological
pathways relevant to regulation of human behaviors.
As with genetic studies in all organisms, the ultimate proof of
functional mutations vs. polymorphisms lies in establishing causality
of the phenotype by the mutation. Many Mendelian human geneticdisease mutations were shown to be causative with multiple
unrelated families co-segregating the DNA variant and disease phe-
notype. However, with human behavioral phenotypes, it is inherently
difficult to obtain multiple families that have the same mutations.
One way to circumvent this is by engineering the DNA variant into
model organisms and to observe whether it produces a similar phe-
notype in the model organism. It is also difficult to demonstrate the
causality of a mutation for a behavioral phenotype if the mutation is
found in multiple random subjects with no family relation and does
not produce a similar phenotype in model organisms. Conversely,
cloning a variant found in only a few individuals but that replicates
the phenotype in every single animal of the model organism
(mouse, fly, etc.) proves causality with no reservations.
Although genetic association studies have provided new insights
into human phenotypes, the inconsistency of the results remains a
major difficulty. This complication may stem from the obstacle in
finding large enough cohorts of subjects with proper phenotyping
data which renders the replication for association study arduous.
Also, the effect sizes are often quite small which calls to question
the cost of such studies vs. the information learned. Rare heritable
CRSD families have so far proven to be useful and offer new genetic
and mechanistic information. However, one persistent challenge in
studying these families is the amount of effort and difficulty in finding
large families to define the potential mutation region with relative
ease. This was one of the major factors limiting researchers to use
the candidate gene approach in the last decade. With the advance-
ment of sequencing technology and the decreasing cost, whole
exome sequencing and whole genome sequencing are becoming
more realistic approaches today. However, new challenges present
themselves with these new technologies such as the enormous effort
required to sort through the large number of SNP variants in order to
identify true functional mutations. Regardless, these newmethods do
offer hope of finding novel human circadian/sleep genes that were
previously impossible.
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